Page 143 - 2019_09-HaematologicaMondo-web

Effects of PEG-asparaginase on CSF asparagine levels
results of the randomized trial AIEOP-BFM
ALL 2000. Blood. 2016;127(17):2101–2112.
22. Asselin B, Rizzari C. Asparaginase pharma- cokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma.
2015;56(8):2273–2280.
23. van den Berg H. Asparaginase revisited.
Leuk Lymphoma. 2011;52(2):168–178.
24. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand?
Expert Opin Biol Ther. 2009;9(1):111–119.
25. Gerrits GP, Trijbels FJ, Monnens LA, et al. Reference values for amino acids in cere- brospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection. Clin Chim Acta.
1989;182(3):271–280.
26. Asselin BL, Lorenson MY, Whitin JC, et al.
Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res. 1991;51(24):6568–6573.
27. Henriksen LT, Nersting J, Raja RA, et al. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in
children with acute lymphoblastic leukaemia. Br J Haematol. 2014;166(2):213– 220.
28. Hawkins DS. Asparaginase pharmacoki- netics after intensive polyethylene glycol- conjugated L-asparaginase therapy for chil- dren with relapsed acute lymphoblastic leukemia. Clin Cancer Res. 2004;10(16): 5335–5341.
29. Ahlke E, Nowak-Göttl U, Schulze- Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induc- tion therapy in children with acute lym- phoblastic leukaemia. Br J Haematol. 1997;96(4):675–681.
30. Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cere- brospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer. 2006;46(1):18–25.
31. Tong WH, Pieters R, de Groot-Kruseman
HA, et al. The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipi- demia. Haematologica. 2014;99(11):1716– 1721.
32. van der Sluis IM, de Groot-Kruseman H, Te Loo M, et al. Efficacy and safety of recombinant E. coli asparaginase in chil- dren with previously untreated acute lym- phoblastic leukemia: a randomized multi- center study of the Dutch Childhood Oncology Group. Pediatr Blood Cancer. 2018;65(8):e27083.
33. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release. 2012;161(2):461–472.
34. Serlin Y, Shelef I, Knyazer B, Friedman A. Anatomy and physiology of the blood– brain barrier. Semin Cell Dev Biol. 2015;38:2–6.
35. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–1972.
haematologica | 2019; 104(9)
1821